Medicine
Bupropion 300 mg extended-release tablet
Bupropion 300 mg extended-release tablet is a generic prescription medicine for oral use, made by 20 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F).
Key facts
- Active ingredient (INN)
- Bupropion
- Brand
- Sold under the generic name
- Strength
- 300 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 500 tablets, 30 tablets, 1000 tablets and 81 more
- Manufacturers
- Zydus LifesciencesIndiaAurobindo PharmaIndiaCamber PharmaceuticalsIndiaGranules IndiaIndiaAccord HealthcareIndiaCiplaIndiaProficient RxRising Pharma HoldingsActavis PharmaA-S Medication Solutions20 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AX12 Bupropion
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 February 2014
- Identifiers
- RxCUI 993541, 993557, 993503DailyMed set ID 8d937ca3-3351-40f1-8192-348ba0c68162, 0b041720-a25d-403e-a72c-601a8bdd8051, 96d87edc-d12b-44b2-e053-2995a90a4e63 +25NDC 68382-354, 70518-4739, 72189-124 +25Application ANDA201567, ANDA215568, ANDA210497 +8
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
A sample of 40 packs from 20 labelers. The register lists 84 packs for this generic presentation, and we confirm the exact pack on the quote.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 500 tablet, extended release in 1 bottle | 65841-780-05 | Zydus LifesciencesIndia | 15 February 2014 |
| 30 tablet, extended release in 1 bottle | 65841-780-06 | Zydus LifesciencesIndia | 15 February 2014 |
| 1000 tablet, extended release in 1 bottle | 65841-780-10 | Zydus LifesciencesIndia | 15 February 2014 |
| 90 tablet, extended release in 1 bottle | 65841-780-16 | Zydus LifesciencesIndia | 15 February 2014 |
| 500 tablet, extended release in 1 bottle | 68382-354-05 | Zydus LifesciencesIndia | 15 February 2014 |
| 30 tablet, extended release in 1 bottle | 68382-354-06 | Zydus LifesciencesIndia | 15 February 2014 |
| 1000 tablet, extended release in 1 bottle | 68382-354-10 | Zydus LifesciencesIndia | 15 February 2014 |
| 90 tablet, extended release in 1 bottle | 68382-354-16 | Zydus LifesciencesIndia | 15 February 2014 |
| 30 tablet, extended release in 1 bottle | 16729-444-10 | Accord HealthcareIndia | 25 March 2019 |
| 500 tablet, extended release in 1 bottle | 16729-444-16 | Accord HealthcareIndia | 25 March 2019 |
| 500 tablet, film coated, extended release in 1 bottle | 59651-512-05 | Aurobindo PharmaIndia | 21 July 2026 |
| 30 tablet, film coated, extended release in 1 bottle | 59651-512-30 | Aurobindo PharmaIndia | 21 July 2026 |
| 90 tablet, film coated, extended release in 1 bottle | 59651-512-90 | Aurobindo PharmaIndia | 21 July 2026 |
| 500 tablet, extended release in 1 bottle | 31722-488-05 | Camber PharmaceuticalsIndia | 1 October 2025 |
| 30 tablet, extended release in 1 bottle | 31722-488-30 | Camber PharmaceuticalsIndia | 1 October 2025 |
| 90 tablet, extended release in 1 bottle | 31722-488-90 | Camber PharmaceuticalsIndia | 1 October 2025 |
| 500 tablet, film coated, extended release in 1 bottle, plastic | 69097-072-12 | CiplaIndia | 25 October 2023 |
| 30 tablet, extended release in 1 bottle | 70010-785-03 | Granules IndiaIndia | 15 December 2022 |
| 500 tablet, extended release in 1 bottle | 70010-785-05 | Granules IndiaIndia | 15 December 2022 |
| 90 tablet, extended release in 1 bottle | 70010-785-09 | Granules IndiaIndia | 15 December 2022 |
| 500 tablet, extended release in 1 bottle | 45963-142-05 | Actavis Pharma | 19 May 2015 |
| 30 tablet, extended release in 1 bottle | 45963-142-30 | Actavis Pharma | 17 February 2015 |
| 90 tablet, extended release in 1 bottle | 45963-142-90 | Actavis Pharma | 15 June 2015 |
| 30 tablet, extended release in 1 package | 62135-876-30 | Chartwell RX | 28 March 2024 |
| 30 tablet, extended release in 1 bottle | 16571-863-03 | Rising Pharma Holdings | 1 August 2022 |
| 90 tablet, extended release in 1 bottle | 16571-863-09 | Rising Pharma Holdings | 1 August 2022 |
| 1000 tablet, extended release in 1 bottle | 16571-863-10 | Rising Pharma Holdings | 1 August 2022 |
| 500 tablet, extended release in 1 bottle | 16571-863-50 | Rising Pharma Holdings | 1 August 2022 |
| 30 tablet, extended release in 1 bottle | 63187-521-30 | Proficient Rx | 1 December 2018 |
| 60 tablet, extended release in 1 bottle | 63187-521-60 | Proficient Rx | 1 December 2018 |
| 90 tablet, extended release in 1 bottle | 63187-521-90 | Proficient Rx | 1 December 2018 |
| 30 tablet, extended release in 1 bottle | 63187-819-30 | Proficient Rx | 1 February 2017 |
| 60 tablet, extended release in 1 bottle | 63187-819-60 | Proficient Rx | 1 February 2017 |
| 180 tablet, extended release in 1 bottle | 63187-819-78 | Proficient Rx | 1 February 2017 |
| 90 tablet, extended release in 1 bottle | 63187-819-90 | Proficient Rx | 1 February 2017 |
| 30 tablet, extended release in 1 bottle | 71205-465-30 | Proficient Rx | 29 July 2020 |
| 60 tablet, extended release in 1 bottle | 71205-465-60 | Proficient Rx | 29 July 2020 |
| 90 tablet, extended release in 1 bottle | 71205-465-90 | Proficient Rx | 29 July 2020 |
| 30 tablet, extended release in 1 bottle | 50090-4749-0 | A-S Medication Solutions | 22 November 2019 |
| 90 tablet, extended release in 1 bottle | 50090-4749-1 | A-S Medication Solutions | 22 November 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 December 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Bupropion 300 mg extended-release tablet.
- Bupropion Hydrochloride (XL) 300 mg extended-release tabletAvailable on requestScieGen PharmaceuticalsUS FDA34 packs
- Bupropion Hydrochloride XL 300 mg extended-release tabletAvailable on requestLupinIndiaUS FDA9 packs
- Bupropion Hydrochloride XL 300 mg extended-release tabletAvailable on requestEpic PharmaUS FDA11 packs
- Bupropion hydrochloride (XL) 300 mg extended-release tabletAvailable on requestLannettUS FDA12 packs
- Bupropion Hydrochloride (XL) 300 mg extended-release tabletAvailable on requestCiplaIndiaUS FDA8 packs
- Bupropion Hydrochloride XL 300 mg extended-release tabletAvailable on requestEpic PharmaUS FDA5 packs
Other strengths and forms of Bupropion
Clinical summary
Bupropion is an aminoketone indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Bupropion for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BupropionFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- WELLBUTRIN SR prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
Need Bupropion 300 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.